Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebronucimab (AK102) in hypercholesterolemia
NCT04358432Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ebronucimab in hypercholesterolemia, sponsored by Akeso, Inc.. Started May 2020; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04358432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358432.